ROACCUTANE Capsules 10 mg

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Product name: ROACCUTANE Capsules 10 mg
Product code: SAP-10112031

1.2. Relevant identified uses of the substance or mixture and uses advised against

Use: oral treatment of severe acne, resistant against other therapies

1.3. Details of the supplier of the safety data sheet

Company information:
Enquiries: Roche Products Pty Limited
Level 8, 30-34 Hickson Road
Millers Point NSW 2000
Australia

Phone: 0061-2-9454-9624
Fax: 0061-2-9971-7401
E-Mail: info.sds@roche.com

Local representation:

1.4. Emergency telephone number

Emergency telephone number: Phone 0061-2-9454-9624

SECTION 2: Hazards identification

2.1 / 2.2. Classification of the substance or mixture / Label elements

GHS Classification

Health Hazards:
3.7 Reproductive toxicity (Category 1A)
H360D May damage the unborn child.

Signalword: Danger
Label:

Precautionary statements:
- P201 Obtain special instructions before use.
- P273 Avoid release to the environment.

Australian Remark:
- HAZARDOUS SUBSTANCE. DANGEROUS GOODS.
2.3. Other hazards

Note
- Women of childbearing potential must not be engaged in any work where dust exposure might occur. In case of doubt a risk assessment is advised.
- Women of childbearing potential have to avoid any overexposure (limit values see chapter 8)

*1 referring to: Isotretinoin

SECTION 3: Composition/information on ingredients

Characterization
consisting of 3.6% Isotretinoin, with the remainder consisting of excipients that are not classified as hazardous

Synonyms
- ROACCUTANE Capsules (soft) 10 mg
- Isotretinoin capsules

UN number
3077

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Concentration</th>
<th>GHS-Classification (pure ingredient)</th>
</tr>
</thead>
</table>
| Isotretinoin 4759-48-2 | 3.6 %         | - Skin corrosion/irritation (Category 2), H315  
|                  |               | - Serious eye damage/eye irritation (Category 2A), H319  
|                  |               | - Reproductive toxicity (Category 1A), H360D  
|                  |               | - Specific target organ toxicity - Single exposure (Category 3), H335  

For the full text of the 'Hazard statements' mentioned in this Section, see Section 16.

SECTION 4: First aid measures

4.1. Description of first aid measures

Eye contact
- rinse immediately with tap water for at least 20 minutes - open eyelids forcibly
- consult a physician

Skin contact
- remove immediately contaminated clothes, wash affected skin with water and soap - do not use any solvents

Inhalation
- remove the casualty to fresh air and keep him/her calm
- in the event of symptoms get medical treatment

Ingestion
- summon a physician immediately
4.2. Most important symptoms and effects, both acute and delayed

Note - no information available

4.3. Indication of any immediate medical attention and special treatment needed

Note to physician - treat symptomatically

SECTION 5: Firefighting measures

5.1. Extinguishing media

Suitable extinguishing media - adapt extinguishing media to surrounding fire conditions

5.2. Special hazards arising from the substance or mixture

Specific hazards - substance is hazardous for water: contain fire-fighting wastewater

5.3. Advice for firefighters

Special method of fire-fighting - for reasons of environmental protection hold the extinguishing agent back

SECTION 6: Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions - ensure adequate ventilation

6.2. Environmental precautions

Environmental protection - do not allow to enter drains or waterways
- if the substance reaches waters or the sewer system, inform the competent authority

6.3. Methods and material for containment and cleaning up

Methods for cleaning up - collect spilled material (avoid dust formation) and hand over to waste removal in sealed containers
SECTION 7: Handling and storage

7.1. Precautions for safe handling

Technical measures
- processing in closed systems, if possible superposed by inert gas (e.g. nitrogen)
- provide suitable exhaust ventilation at the processing machines
- take precautionary measures against electrostatic charging
- avoid formation and deposition of dust

7.2. Conditions for safe storage, including any incompatibilities

Storage conditions
- below 25 °C
- protected from light

Validity
- see "best use before" date stated on the label

SECTION 8: Exposure controls/personal protection

8.1. Control parameters

Threshold value (Roche) air
- IOEL (Internal Occupational Exposure Limit): 0.002 mg/m³

8.2. Exposure controls

General protective and hygiene measures
- instruction of employees mandatory
- shower after work recommended

Respiratory protection
- in case of open handling or accidental release:
  particle mask or respirator with independent air supply

Hand protection
- protective gloves (e.g. made of neoprene, nitrile or butyl rubber)

Eye protection
- safety glasses

Analytics
- sampling on glassfiber filter and chemical determination of the active compound (e.g. HPLC)

*1 referring to: Isotretinoin

SECTION 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

Colour
- brownish-red
- country-specific

Form
- gelatin capsule soft
9.2. Other information

Note - no information available

*1 referring to: Isotretinoin

SECTION 10: Stability and reactivity

10.1. Reactivity

Note - no information available

10.2. Chemical stability

Note - no information available

10.3. Possibility of hazardous reactions

Note - no information available

10.4. Conditions to avoid

Conditions to avoid - light (gradual decomposition) *1
- warming (gradual decomposition) *1

10.5. Incompatible materials

Note - no information available

10.6. Hazardous decomposition products

Note - no information available

*1 referring to: Isotretinoin

SECTION 11: Toxicological information

11.1. Information on toxicological effects

Acute toxicity - \( \text{LD}_{50} > 4'000 \text{ mg/kg} \) (oral, rat) *1
ROACCUTANE Capsules 10 mg

Local effects - no information available
Sensitization - no information available
Mutagenicity - not mutagenic (various test systems) *1
Carcinogenicity - not cancerogenic *1
Reproductive toxicity - teratogenic (human and animal) *1
STOT-single exposure - no information available
STOT-repeated exposure - no information available
Aspiration hazard - no information available

Note - dosage: daily 0.5 - 1.0 mg/kg (oral) *1
- half-life of elimination: between 7 - 39 hours (average approx. 20 hours) *1
- systemic symptoms: signs of vitamin A hypervitaminosis (dryness of mucous membranes, exanthems, pruritus; high doses: signs of intracranial pressure like headache, vomiting, etc.) *1

*1 referring to: Isotretinoin

SECTION 12: Ecological information

12.1. Toxicity

Ecotoxicity - strongly toxic for planktonic crustaceans (Daphnia magna)
EC_{50} (48 h) 2.06 mg/l
(FDA Technical Assistance Document No. 4.08) *1
- highly toxic for fish (rainbow trout)
LC_{100} (96 h) 0.61 mg/l
LC_{50} (96 h) 0.52 mg/l
LC_{0} (96 h) 0.45 mg/l
NOEC (96 h) 0.05 mg/l
(OECD No. 203) *1
- barely toxic for microorganisms (activated sludge)
LC_{50} (3 h) > 100 mg/l
(Activated Sludge Respir. Inhib. Test, OECD No. 209) *1

12.2. Persistence and degradability

Inherent biodegradability - inherently biodegradable
59 %, 28 days
(MITI Test II, OECD No. 302 C) *1

12.3. Bioaccumulative potential

Note - no information available

Date: 3.11.17/LS (SEISMO) Replacing edition of: 31.7.15
12.4. Mobility in soil
Note - no information available

12.5. Results of PBT and vPvB assessment
Note - no information available

12.6. Other adverse effects
Note - the substance shows a potential of bioaccumulation

*1 referring to: Isotretinoin

SECTION 13: Disposal considerations

13.1. Waste treatment methods
Waste from residues - return to supplier or hand over to authorised disposal company
- observe local/national regulations regarding waste disposal
- incinerate in qualified installation with flue gas scrubbing
- medicines should not be disposed of via wastewater

SECTION 14: Transport information

<table>
<thead>
<tr>
<th>IATA</th>
<th>Class</th>
<th>UN/ID</th>
<th>PG</th>
<th>PI</th>
<th>Label</th>
<th>Mark</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>3077</td>
<td>III</td>
<td></td>
<td>956/956</td>
<td>9</td>
<td>EHS</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>IMDG</th>
<th>Class</th>
<th>UN</th>
<th>PG</th>
<th>EmS</th>
<th>PI</th>
<th>Label</th>
<th>Mark</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>3077</td>
<td>III</td>
<td></td>
<td>F-A S-F</td>
<td>P002/IBC08</td>
<td>9</td>
<td>marine pollutant</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>RID/ADR</th>
<th>Class</th>
<th>UN</th>
<th>PG</th>
<th>Haz.no</th>
<th>PI</th>
<th>Label</th>
<th>Mark</th>
<th>Classif. code</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>3077</td>
<td>III</td>
<td>90</td>
<td>P002/IBC08</td>
<td>9</td>
<td>EHS</td>
<td>M7</td>
<td></td>
</tr>
</tbody>
</table>

Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.

Technical name: Isotretinoin mixture
SECTION 15: Regulatory information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Water hazard class (Germany) 3: strongly hazardous for water (according to directive AwSV of 18.04.2017)

Regulatory status (Australia) - This product has been approved by the Therapeutic Goods Administration (TGA); AUST R 50840

SECTION 16: Other information

Safety-lab number
- BS-2435
- BS-7164
- BS-9093

Full text of H-Statements referred to under section 3
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
H360D May damage the unborn child.

Note
- Please note this Safety Data Sheet for the bulk product does not apply for the finished, packaged medicinal product intended for the final user.

Edition documentation
- changes from previous version in sections 3, 15

*1 referring to: Isotretinoin

The information in this safety data sheet is based on current scientific knowledge. It should not be taken as expressing or implying any warranty concerning product characteristics.
SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Product name           ROACCUTANE Capsules 20 mg
Product code           SAP-10052099

1.2. Relevant identified uses of the substance or mixture and uses advised against

Use                   - oral treatment of severe acne, resistant against other therapies

1.3. Details of the supplier of the safety data sheet

Company information   Local representation:
Enquiries:             Roche Products Pty Limited
                       Level 8, 30-34 Hickson Road
                       Millers Point NSW 2000
                       Australia

                       Phone       0061-2-9454-9624
                       Fax         0061-2-9971-7401
                       E-Mail      info.sds@roche.com

1.4. Emergency telephone number

Emergency telephone number Phone       0061-2-9454-9624

SECTION 2: Hazards identification

2.1. / 2.2. Classification of the substance or mixture / Label elements

GHS Classification

Health Hazards:
3.7 Reproductive toxicity (Category 1A)
H360D May damage the unborn child.

Signalword: Danger
Label:

Precautionary statements:
- P201 Obtain special instructions before use.
- P273 Avoid release to the environment.

Australian Remark
- HAZARDOUS SUBSTANCE. DANGEROUS GOODS.
2.3. Other hazards

Note - Women of childbearing potential must not be engaged in any work where dust exposure might occur. In case of doubt a risk assessment is advised.
- women of childbearing potential have to avoid any overexposure (limit values see chapter 8)

*1 referring to: Isotretinoin

SECTION 3: Composition/information on ingredients

Characterization consisting of 4% Isotretinoin, with the remainder consisting of excipients that are not classified as hazardous

Synonyms - ROACCUTANE Capsules (soft) 20 mg
- Isotretinoin capsules

UN number 3077

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Concentration</th>
<th>GHS-Classification (pure ingredient)</th>
</tr>
</thead>
</table>
| Isotretinoin 4759-48-2 | 3.9 %         | - Skin corrosion/irritation (Category 2), H315
|                   |               | - Serious eye damage/eye irritation (Category 2A), H319
|                   |               | - Reproductive toxicity (Category 1A), H360D
|                   |               | - Specific target organ toxicity - Single exposure (Category 3), H335

For the full text of the 'Hazard statements' mentioned in this Section, see Section 16.

SECTION 4: First aid measures

4.1. Description of first aid measures

Eye contact - rinse immediately with tap water for at least 20 minutes - open eyelids forcibly
- consult a physician

Skin contact - remove immediately contaminated clothes, wash affected skin with water and soap - do not use any solvents

Inhalation - remove the casualty to fresh air and keep him/her calm
- in the event of symptoms get medical treatment

Ingestion - summon a physician immediately
4.2. Most important symptoms and effects, both acute and delayed

Note - no information available

4.3. Indication of any immediate medical attention and special treatment needed

Note to physician - treat symptomatically

SECTION 5: Firefighting measures

5.1. Extinguishing media

Suitable extinguishing media - adapt extinguishing media to surrounding fire conditions

5.2. Special hazards arising from the substance or mixture

Specific hazards - substance is hazardous for water: contain fire-fighting wastewater

5.3. Advice for firefighters

Special method of fire-fighting - for reasons of environmental protection hold the extinguishing agent back

SECTION 6: Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions - ensure adequate ventilation

6.2. Environmental precautions

Environmental protection - do not allow to enter drains or waterways
- if the substance reaches waters or the sewer system, inform the competent authority

6.3. Methods and material for containment and cleaning up

Methods for cleaning up - collect spilled material (avoid dust formation) and hand over to waste removal in sealed containers
SECTION 7: Handling and storage

7.1. Precautions for safe handling

Technical measures
- processing in closed systems, if possible superposed by inert gas (e.g. nitrogen)
- provide suitable exhaust ventilation at the processing machines
- take precautionary measures against electrostatic charging
- avoid formation and deposition of dust

7.2. Conditions for safe storage, including any incompatibilities

Storage conditions
- below 25 °C
- protected from light

Validity
- see "best use before" date stated on the label

SECTION 8: Exposure controls/personal protection

8.1. Control parameters

Threshold value (Roche) air
- IOEL (Internal Occupational Exposure Limit): 0.002 mg/m³

8.2. Exposure controls

General protective and hygiene measures
- instruction of employees mandatory
- shower after work recommended

Respiratory protection
- in case of open handling or accidental release:
  particle mask or respirator with independent air supply

Hand protection
- protective gloves (eg made of neoprene, nitrile or butyl rubber)

Eye protection
- safety glasses

Analytics
- sampling on glassfiber filter and chemical determination of the active compound (eg HPLC)

*1 referring to: Isotretinoin

SECTION 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

Colour
- half brown-red, half opaque white
- country-specific

Form
- gelatin capsule soft
ROACCUTANE Capsules 20 mg

Solubility
< 100 mg/l, water (25 °C)  
3'000 mg/l, peanut oil (25 °C)  
12'000 mg/l, ethanol (25 °C)  
15'000 mg/l, n-octanol (25 °C)  
24'000 mg/l, acetone (25 °C)  

Partition coefficient
\[ \log P_{\text{ow}} 6.6 \text{ (octanol/water°C)} \]  

9.2. Other information

Note - no information available

*1 referring to: Isotretinoin

SECTION 10: Stability and reactivity

10.1. Reactivity

Note - no information available

10.2. Chemical stability

Note - no information available

10.3. Possibility of hazardous reactions

Note - no information available

10.4. Conditions to avoid

Conditions to avoid - light (gradual decomposition)  
- warming (gradual decomposition)  

10.5. Incompatible materials

Note - no information available

10.6. Hazardous decomposition products

Note - no information available

*1 referring to: Isotretinoin

SECTION 11: Toxicological information

11.1. Information on toxicological effects

Acute toxicity - \( \text{LD}_{50} \) > 4'000 mg/kg (oral, rat)  

*1
### Local effects
- no information available

### Sensitization
- no information available

### Mutagenicity
- not mutagenic (various test systems)

### Carcinogenicity
- not cancerogenic

### Reproductive toxicity
- teratogenic (human and animal)

### STOT-single exposure
- no information available

### STOT-repeated exposure
- no information available

### Aspiration hazard
- no information available

### Note
- dosage: daily 0.5 - 1.0 mg/kg (oral)
- half-life of elimination: between 7 - 39 hours (average approx. 20 hours)
- systemic symptoms: signs of vitamin A hypervitaminosis (dryness of mucous membranes, exanthems, pruritus; high doses: signs of intracranial pressure like headache, vomiting, etc.)

**1** referring to: Isotretinoin

## SECTION 12: Ecological information

### 12.1. Toxicity

#### Ecotoxicity
- strongly toxic for planktonic crustaceans (Daphnia magna)
  \( EC_{50} \) (48 h) 2.06 mg/l
  (FDA Technical Assistance Document No. 4.08)
- highly toxic for fish (rainbow trout)
  \( LC_{100} \) (96 h) 0.61 mg/l
  \( LC_{50} \) (96 h) 0.52 mg/l
  \( LC_{0} \) (96 h) 0.45 mg/l
  NOEC (96 h) 0.05 mg/l
  (OECD No. 203)
- barely toxic for microorganisms (activated sludge)
  \( LC_{50} \) (3 h) > 100 mg/l
  (Activated Sludge Respir. Inhib. Test, OECD No. 209)

### 12.2. Persistence and degradability

#### Inherent biodegradability
- inherently biodegradable
  59 %, 28 days
  (MITI Test II, OECD No. 302 C)

### 12.3. Bioaccumulative potential

#### Note
- no information available
12.4. Mobility in soil

Note - no information available

12.5. Results of PBT and vPvB assessment

Note - no information available

12.6. Other adverse effects

Note - the substance shows a potential of bioaccumulation

*1 referring to: Isotretinoin

SECTION 13: Disposal considerations

13.1. Waste treatment methods

Waste from residues - return to supplier or hand over to authorised disposal company
- observe local/national regulations regarding waste disposal
- incinerate in qualified installation with flue gas scrubbing
- medicines should not be disposed of via wastewater

SECTION 14: Transport information

<table>
<thead>
<tr>
<th>IATA</th>
<th>Class</th>
<th>UN/ID</th>
<th>PG</th>
<th>PI</th>
<th>Label</th>
<th>Mark</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>3077</td>
<td>III</td>
<td></td>
<td>956/956</td>
<td>9</td>
<td>EHS</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>IMDG</th>
<th>Class</th>
<th>UN</th>
<th>PG</th>
<th>EmS</th>
<th>PI</th>
<th>Label</th>
<th>Mark</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>3077</td>
<td>III</td>
<td>F-A S-F</td>
<td>P002/IBC08</td>
<td>9</td>
<td>marine pollutant</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>RID/ADR</th>
<th>Class</th>
<th>UN</th>
<th>PG</th>
<th>Haz.no</th>
<th>PI</th>
<th>Label</th>
<th>Mark</th>
<th>Classif. code</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>3077</td>
<td>III</td>
<td>90</td>
<td>P002/IBC08</td>
<td>9</td>
<td>EHS</td>
<td>M7</td>
<td></td>
</tr>
</tbody>
</table>

Proper shipping name ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.

Technical name Isotretinoin mixture
SECTION 15: Regulatory information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Water hazard class (Germany) 3: strongly hazardous for water (according to directive AwSV of 18.04.2017)

Regulatory status (Australia) - This product has been approved by the Therapeutic Goods Administration (TGA); AUST R 50839

SECTION 16: Other information

Safety-lab number - BS-2435 *1
- BS-7164 *1
- BS-9093 *1

Full text of H-Statements referred to under section 3
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
H360D May damage the unborn child.

Note - Please note this Safety Data Sheet for the bulk product does not apply for the finished, packaged medicinal product intended for the final user.

Edition documentation - changes from previous version in sections 3, 15

*1 referring to: Isotretinoin

The information in this safety data sheet is based on current scientific knowledge. It should not be taken as expressing or implying any warranty concerning product characteristics.